Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why
06:46pm, Monday, 29'th Jan 2024
The latest trading day saw AbbVie (ABBV) settling at $163.91, representing a -0.3% change from its previous close.
Pharma industry to get US government price cut proposals by Thursday
11:35am, Monday, 29'th Jan 2024
Pharmaceutical companies are due to receive by Thursday the U.S. government's opening proposal for discounts it is seeking on 10 high-cost medicines, an important step in the Medicare health program's
2 High-Yield Healthcare Stocks to Buy With Both Hands and 1 to Avoid for Now
11:42am, Sunday, 28'th Jan 2024
Medtronic's global medical device business has supported annual dividend raises since 1978, and it's well positioned for more growth. AbbVie's lead drug fell off a patent cliff last year, but soaring
Why Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's Prospects
02:56am, Sunday, 28'th Jan 2024
Aldeyra Therapeutics is a biotech company focused on developing treatments for immune-mediated inflammatory diseases, with its leading drug candidate being Reproxalap for dry eye and allergic conjunct
AbbVie And Merck: Defensive Healthcare Plays Providing Income
12:24pm, Friday, 26'th Jan 2024
Healthcare had a mediocre performance in 2023, but it remains a suitable addition to a diversified portfolio due to its defensive characteristics. AbbVie Inc. and Merck & Co., Inc. are attractive heal
Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline
11:06am, Friday, 26'th Jan 2024
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Dividend Stars Every Investor Should Own to Survive a Market Crash
06:44pm, Wednesday, 24'th Jan 2024
One of the best reasons to invest in dividend stocks is how well they hold up when the stock market falls. Whether it's a correction, a bear market, a recession, a depression or a full-on market crash
Instead Of Buying A Rolex, I'm Investing $20,000 In These 2 Stocks, Yielding Up To 7%
10:30am, Wednesday, 24'th Jan 2024
In this article, I start by explaining why I have decided to refrain from buying a fancy watch. Instead, I decided to invest in two high-yield dividend stocks. As the market valuation has turned unfav
7 Dividend Aristocrats That Will Pay You for Years to Come
11:19pm, Monday, 22'nd Jan 2024
Dividend Aristocrats are stocks that have been increasing dividends for the last 25 years. Inherently, these companies have deep stability and for that reason continue to be attractive.
AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
06:51pm, Monday, 22'nd Jan 2024
AbbVie (ABBV) closed at $165.39 in the latest trading session, marking a +0.38% move from the prior day.
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Monday, 22'nd Jan 2024
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
7 Highest Yielding Dividend Aristocrats Like AbbVie Are The Best 2024 Ideas Now
10:40am, Sunday, 21'st Jan 2024
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE Ever wanted an extra set of eyes on an investment you're considering?
Final Trades: Verizon, Abbvie, Gilead Sciences and Arch Capital Group
01:39pm, Wednesday, 17'th Jan 2024
Jenny Harrington, Gilman Hill Asset Management CEO, Jim Lebenthal, chief equity strategist at Cerity Partners, Joe Terranova, senior managing director at Virtus Investment Partners, and Rob Sechan, ma
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note
06:48pm, Tuesday, 16'th Jan 2024
In the closing of the recent trading day, AbbVie (ABBV) stood at $161.48, denoting a -0.57% change from the preceding trading day.
Charts turn bullish on health-care stocks as sector takes early lead in 2024
11:29am, Tuesday, 16'th Jan 2024
Chart-watchers are growing increasingly bullish on health-care stocks now that they have become the best-performing sector of the S&P 500 so far in 2024, according to Dow Jones Market Data. Analysts h
